Biotech Stocks Plummet After Bone Disease Treatment Failures
TL;DR Summary
Ultragenyx and Mereo's late-stage clinical trial for a rare bone disease drug has failed, marking a significant setback for the development program.
- Ultragenyx, Mereo crash on late-stage bone disease failure Endpoints News
- Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate Reuters
- Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta Yahoo Finance
- These biotech stocks are getting hammered by shocking brittle-bone treatment study results MarketWatch
- Ultragenyx vows 'significant' cutbacks as failed study wipes more than $1 billion from Novato biotech's market value The Business Journals
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
63%
59 → 22 words
Want the full story? Read the original article
Read on Endpoints News